Education
About Us
Working with TipRanks
Follow Us
Cencora (COR)
NYSE:COR
COR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$214.77 - $296.65
Previous CloseN/A
Volume440.68K
Average Volume (3M)1.97M
Market Cap
$54.76B
Enterprise Value$48.81B
Total Cash (Recent Filing)$1.20B
Total Debt (Recent Filing)$1.36B
Price to Earnings (P/E)40.2
Beta0.16
Next Earnings
May 07, 2025EPS Estimate
4.11Last Dividend Ex-Date
Feb 14, 2025Dividend Yield0.75%
Share Statistics
EPS (TTM)7.03
Shares Outstanding193,917,080
10 Day Avg. Volume1,944,196
30 Day Avg. Volume1,966,507
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.17
Price to Cash Flow (P/CF)-4.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.93
Enterprise Value/Ebitda15.38
Forecast
1Y Price Target
$299.20Price Target Upside4.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
---
Bulls Say, Bears Say
Bulls Say
EarningsThe company's adjusted EPS beat estimates, showcasing strong financial performance.
GuidanceThe price target is increased to $274 due to stronger performance in the core U.S. market.
Market PositionCOR has a strong position within the market, notably in specialty.
Bears Say
Customer RelationshipThere is uncertainty around the relationship with WBA, which is COR’s largest customer, as recent commentary sounded somewhat adversarial.
ValuationValuation feels relatively full compared to significant discounts across much of the rest of the coverage universe.
---
Ownership Overview
6.82% Insiders
26.68% Mutual Funds
0.56% Other Institutional Investors
42.24% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
COR FAQ
What was Cencora’s price range in the past 12 months?
Cencora lowest stock price was $214.77 and its highest was $296.65 in the past 12 months.
What is Cencora’s market cap?
Cencora’s market cap is $54.76B.
When is Cencora’s upcoming earnings report date?
Cencora’s upcoming earnings report date is May 07, 2025 which is in 11 days.
How were Cencora’s earnings last quarter?
Cencora released its earnings results on Feb 05, 2025. The company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.502 by $0.228.
Is Cencora overvalued?
According to Wall Street analysts Cencora’s price is currently Undervalued.
Does Cencora pay dividends?
Cencora pays a Quarterly dividend of $0.55 which represents an annual dividend yield of 0.75%. See more information on Cencora dividends here
What is Cencora’s EPS estimate?
Cencora’s EPS estimate is 4.11.
How many shares outstanding does Cencora have?
Cencora has 193,917,080 shares outstanding.
What happened to Cencora’s price movement after its last earnings report?
Cencora reported an EPS of $3.73 in its last earnings report, beating expectations of $3.502. Following the earnings report the stock price went up 0.681%.
Which hedge fund is a major shareholder of Cencora?
Currently, no hedge funds are holding shares in COR
---
Cencora Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$299.20 (4.65% Upside)
$299.20 (4.65% Upside)
Blogger Sentiment
Bullish
COR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 409.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $316.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 23.5%
Last 30 Days ▲ 23.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.74%
12-Months-Change
Fundamentals
Return on Equity
245.32%
Trailing 12-Months
Asset Growth
6.75%
Trailing 12-Months
Company Description
Cencora
Cencora, Inc. sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The company also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; and pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. The company's International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; and distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers and hospitals primarily in Europe. This segment also provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
---
COR Company Deck
---
COR Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue and EPS growth, particularly in the U.S. healthcare solutions segment, and the strategic acquisition of RCA. Despite these positive developments, there were challenges such as decreased gross profit margin, subdued international operation results, and negative free cash flow. The overall sentiment is cautiously optimistic with strong underlying performance offset by some challenges.Read More>---
COR Revenue Breakdown
89.54% U.S. Healthcare Solutions
10.46% International Healthcare Solutions
---
COR Stock 12 Month Forecast
Average Price Target
$299.20
▲(4.65% Upside)
Technical Analysis
Best Analysts Covering COR
1 Year
1 Year Success Rate
40/42 ratings generated profit
1 Year Average Return
+22.61%
reiterated a buy rating 2 months ago
Copying Eric Coldwell's trades and holding each position for 1 Year would result in 95.24% of your transactions generating a profit, with an average return of +22.61% per trade.
---